Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
HIV HGM BioBank, Madrid, Spain.
AIDS Res Ther. 2022 May 25;19(1):22. doi: 10.1186/s12981-022-00448-1.
The initial cases of COVID-19 appeared in December 2019 and Spain was one of the most affected countries during the first wave (March to June). Since then, HIV HGM BioBank has been restructured as an established Paediatrics and Adults HIV_COVID-19 BioBank that aims at the long-term storage of samples obtained from not only HIV-1, but also from COVID-19 patients and HIV-1_COVID-19 coinfected patients.
HIV HGM BioBank holds high quality biological samples from newborns, children, adolescents and adults with their associated clinical data. Research groups trying to establish large networks focused on research on specific clinical problems in epidemiology, biology, routes of transmission and therapies, are potential users of the clinical samples and of associated data of HIV-1_COVID-19 HGM BioBank.
The HIV HGM BioBank is an academic and ethical enterprise complying with all the legal regulatory rules to provide service to the society. HIV_COVID-19 HGM BioBank has been repurposed to offer an important resource for global research of COVID-19 in newborns, children, adolescents, adults and elders to study the biological effect of the pandemic.
Herein, we present a description of how HIV HGM BioBank has rapidly become an indispensable structure in modern biomedical research, including COVID-19 research.
COVID-19 的最初病例出现在 2019 年 12 月，西班牙是第一波疫情（3 月至 6 月）期间受影响最严重的国家之一。从那时起，HIV HGM 生物银行已重组为一个常设的儿科和成人 HIV_COVID-19 生物银行，旨在长期储存不仅来自 HIV-1 患者，还来自 COVID-19 患者和 HIV-1_COVID-19 合并感染患者的样本。
HIV HGM 生物银行拥有高质量的新生儿、儿童、青少年和成人的生物样本及其相关临床数据。研究小组试图建立大型网络，专注于流行病学、生物学、传播途径和治疗方法等特定临床问题的研究，是 HIV-1_COVID-19 HGM 生物银行的临床样本和相关数据的潜在使用者。
HIV HGM 生物银行是一个学术和伦理企业，遵守所有法律监管规则，为社会提供服务。HIV_COVID-19 HGM 生物银行已被重新用于为新生儿、儿童、青少年、成年人和老年人的 COVID-19 全球研究提供重要资源，以研究大流行的生物学效应。
本文介绍了 HIV HGM 生物银行如何迅速成为现代生物医学研究（包括 COVID-19 研究）不可或缺的结构。
